Skip to main content

Animations

We are charting the path to a future free from Parkinson’s. Your support will get us there.

Targeting the WDR Domain of LRRK2 for Parkinson’s Disease Therapy

Study Rationale:

Mutations in the LRRK2 gene are a major genetic cause of Parkinson’s disease (PD), and most drug development has focused on blocking LRRK2’s kinase activity. However, a different part of the protein, called the WD40 repeat (WDR) domain, is also essential for LRRK2 toxicity in neurons. Targeting this domain may offer a new and potentially safer way to treat PD.

Hypothesis:

We hypothesize that small molecules designed to bind the WDR domain of LRRK2 can reduce its harmful effects in neurons and serve as a basis for developing a new class of PD therapies.

Study Design:

We will use advanced computer modeling and lab testing to design and refine small molecules that can bind tightly to the WDR domain of LRRK2 and can enter the brain. We will evaluate these molecules for their ability to block harmful LRRK2 activity in cells and to meet drug-like criteria. Promising compounds will be further optimized and tested for their potential to move toward clinical development.

Impact on Diagnosis/Treatment of Parkinson’s disease:

This project may lead to a new kind of treatment for PD by targeting a part of LRRK2 that is distinct from the kinase domain, potentially offering greater selectivity and fewer side effects.

Next Steps for Development:

If successful, the most promising compounds will advance to lead optimization and preclinical development, with the goal of creating a first-inclass drug targeting the WDR domain of LRRK2.


Researchers

  • Dmitri Kireev, PhD

    Columbia, MO United States


  • Jean-Marc Taymans, PhD,IR

    Lille France


  • Olivier Finance, PhD, PharmD

    Saint-Grégoire France


  • Christina Jacob, PhD

    Saint-Grégoire France


  • Nelly Piton, PhD

    Saint-Grégoire France


Discover More Grants

Search by Related Keywords

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.